The number
Every one of the 17 pharma and healthcare funds with a full one-year record made money in the year to 1 October 2026. The median gained 17.50%; the weakest, Tata India Pharma & Healthcare, still made 7.91%.
That is unusual in a year when the median fund in the whole Sectoral/Thematic category (256 funds) returned 1.25%, and when 30 of 33 large-cap funds lost money.
All figures are for the Direct plan, Growth option, computed from daily NAVs to 1 October 2026 (30 September for one fund). Returns of a year or more are compounded annual rates. We counted funds whose names say pharma, healthcare or health & wellness; there are 19, and two have no returns yet.
The ranking
| Fund (Direct, Growth) | 1 year | 3 years | 5 years |
|---|---|---|---|
| Kotak Healthcare | 28.78% | ||
| HDFC Pharma and Healthcare | 26.61% | 30.26% | |
| PGIM India Healthcare | 25.67% | ||
| WhiteOak Capital Pharma and Healthcare | 22.13% | ||
| Bajaj Finserv Healthcare | 20.97% | ||
| Mirae Asset Healthcare | 20.26% | 21.71% | 15.34% |
| SBI Healthcare Opportunities | 20.19% | 22.78% | 17.78% |
| quant Healthcare | 18.68% | 20.15% | |
| Aditya Birla Sun Life Pharma and Healthcare | 17.50% | 20.06% | 13.98% |
| DSP Healthcare | 17.35% | 20.84% | 15.40% |
| UTI Healthcare | 16.65% | 22.50% | 15.32% |
| LIC MF Healthcare | 13.76% | 20.83% | |
| ITI Pharma and Healthcare | 12.44% | 18.84% | |
| Nippon India Pharma | 12.36% | 17.58% | 13.52% |
| Baroda BNP Paribas Health and Wellness | 11.88% | ||
| ICICI Prudential Healthcare | 7.97% | 21.06% | 15.55% |
| Tata India Pharma & Healthcare | 7.91% | 18.22% | 14.01% |
Four of the top five are recent launches with no three-year record yet; the older funds with a five-year record are bunched between 13.5% and 17.8% a year.
What the longer record says
Twelve funds have three years. Their median is about 20.8% a year, with a tight range apart from one outlier: eleven funds sit between 17.6% and 22.8%, and HDFC Pharma and Healthcare is at 30.26%. Eight funds have five years, with a median of about 15.3% a year; SBI Healthcare Opportunities leads on 17.78%.
The one-year table and the three-year table disagree about two funds. ICICI Prudential Healthcare is second-last over one year (7.97%) but fifth over three (21.06%). Nippon India Pharma is near the bottom on both clocks.
Risk
Pharma funds were calmer than the sector average: the median volatility was 13.5% against 15.6% for the whole Sectoral/Thematic category. The three-year falls were mostly shallow, between 13.5% (SBI) and 17.1% (ITI). The exception is quant Healthcare, with 17.4% volatility and a worst three-year fall of 25.2% even though its return is middling.
Reading this
The strength of the last year is broad: every fund gained, so it is a story about the sector, not about fund selection. A sector fund puts one bet in one basket, and the best-ranked funds this year are the ones with the shortest records. What the table cannot say is whether the sector will keep this lead.
To see what these funds hold, see pharma stocks in mutual fund portfolios. To compare the sector's counterpart, see technology funds, where the picture is the reverse.
Returns are historical and computed from NAVs; they are not a forecast. Past returns do not indicate future performance.
Frequently asked questions
How have pharma and healthcare funds performed over the last year?
All 17 pharma and healthcare funds (Direct plan, Growth option) with a full one-year record gained in the year to 1 October 2026. The median made 17.50%, from 7.91% (Tata India Pharma & Healthcare) to 28.78% (Kotak Healthcare).
What is the three-year return of pharma funds?
The median was about 20.8% a year across 12 funds with a three-year record. HDFC Pharma and Healthcare led at 30.26% and Nippon India Pharma trailed at 17.58%.
Are pharma funds less volatile than other sector funds?
They were calmer than most. The median volatility was 13.5% and the median worst three-year fall was about 15.9%, against 15.6% volatility for the median fund in the whole Sectoral/Thematic category.
This is commentary on published data, not investment advice. WealthTicker is not a SEBI-registered adviser or distributor. Figures are WealthTicker’s own calculations from public data — AMFI’s fund NAVs and disclosures, NSE’s index and FII/DII files, and the fund houses’ monthly portfolios (how we calculate). They are as of the dates stated and can be revised by their source.
Keep reading
Pharma and healthcare funds in June 2026: up 10% this year
On 18 June 2026 the median healthcare fund was up 10.03% for 2026 while the Nifty 50 was down 7.57%. Returns over 1, 3 and 5 years against the Nifty Pharma.
Business cycle funds: all 10 with 3 years beat Nifty 500
19 business cycle funds hold ₹42,278 crore. All 10 with three years beat the Nifty 500 TRI to October 2026, at a median 12.4% a year. Banks lead most of them.
ESG mutual funds: 3 of 8 beat the Nifty 500 over 3 years
Ten active ESG funds hold ₹9,880 crore, three-quarters of it in exclusion strategies. Over three years to 9 October 2026, three of eight beat the Nifty 500 TRI.
